Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder
Lecanemab Phase III Readout Next Major Milestone
Executive Summary
In addition to its uncertain attempt at near-term revenue growth with Eisai-partnered lecanemab, Biogen recently ended multiple R&D programs and will pay $900m to settle a whistleblower lawsuit.
You may also be interested in...
Biogen’s Singhal Offers A Look Into Company's Pipeline Review
Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.
Biogen Agrees To One Of Largest FCA Settlements Without DOJ Intervention
Company to pay $900m to resolve claims it paid kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. Whistleblower sought damages based on the number of prescriptions written after a healthcare provider received a kickback from Biogen.